Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Source: European Journal of Cancer - March 1, 2021 Category: Cancer & Oncology Authors: Takeshi Fukumoto, Nobuyuki Horita Tags: Letter to the Editor Source Type: research